Vir Biotechnology names CEO Marianne De Backer President

Vir Biotechnology, Inc. has expanded the role of its Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA, appointing her to the additional position of President effective March 4, 2026.

Accepted by SEC EDGAR 03/04/2026 - 04:01 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology, Inc. has expanded the role of its Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA, appointing her to the additional position of President effective March 4, 2026. She will now serve as CEO, principal executive officer, and President.

The company notes there are no arrangements or understandings with any other person related to her appointment, no family relationships with any director or executive officer, and no transactions involving her that require related-party disclosure. Biographical details are incorporated by reference from Vir’s April 17, 2025 proxy statement.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did Vir (VIR) announce on March 4, 2026?

Vir Biotechnology expanded Marianne De Backer’s responsibilities, naming her President in addition to Chief Executive Officer and principal executive officer. This consolidates top leadership roles under one executive while maintaining the existing board and management structure as described in the disclosure.

Who is Marianne De Backer in Vir Biotechnology’s (VIR) leadership team?

Marianne De Backer, M.Sc., Ph.D., MBA, serves as Vir Biotechnology’s Chief Executive Officer, principal executive officer, and now President. Her detailed biographical information is incorporated by reference from Vir’s definitive proxy statement filed on April 17, 2025 with the Securities and Exchange Commission.

Were there special arrangements behind Marianne De Backer’s new President role at Vir (VIR)?

The company states there are no arrangements or understandings with any other person under which Marianne De Backer was named President. This suggests the appointment was a board decision without side agreements or negotiated arrangements disclosed in connection with the new title.

Does Marianne De Backer have family relationships with Vir (VIR) directors or executives?

Vir Biotechnology reports that Marianne De Backer has no family relationship with any of the company’s directors or executive officers. This disclosure helps clarify governance independence regarding her appointment as President and reinforces that no familial ties influenced the board’s decision.

Are there related-party transactions involving Marianne De Backer at Vir (VIR)?

The company states that Marianne De Backer has no direct or indirect interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K. This indicates no reportable related-party transactions involving her are associated with this leadership change at Vir Biotechnology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001706431 0001706431 2026-03-04 2026-03-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 4, 2026

Vir Biotechnology, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39083		81-2730369
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1800 Owens Street, Suite 900
San Francisco, California		94158
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 906-4324

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		VIR		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 4, 2026, the Board of Directors of Vir Biotechnology, Inc. (Vir Bio) appointed Marianne De Backer, M.Sc., Ph.D., MBA, Vir Bio’s Chief Executive Officer and principal executive officer, to the additional position of President.

Biographical information regarding Dr. De Backer that is responsive to Items 401(b) and (e) of Regulation S-K is incorporated by reference herein from Vir Bio’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 17, 2025.

There are no arrangements or understandings between Dr. De Backer and any other person pursuant to which she was named as President of Vir Bio, and there is no family relationship between Dr. De Backer and any of Vir Bio’s directors or executive officers. Dr. De Backer has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						VIR BIOTECHNOLOGY, INC.
Date: March 4, 2026				By:		/s/ Vanina de Verneuil
						Vanina de Verneuil, J.D. Executive Vice President, General Counsel and Corporate Secretary

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB